Open Source Therapeutics Co. Ltd. has identified bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, epilepsy, hypertension, psoriasis, rheumatoid arthritis, stroke and ulcerative colitis, among others.